Zortix
Ask Zortix…⌘KSign in

What finance podcasts are saying aboutNike Inc.NKENYSE

According to Zortix's podcast index, Nike Inc. (NKE) was discussed on 12 finance podcasts across 16 episodes in the 30 days to 19 Oct 2026, generating 16 attributed ideas, most coverage from Bloomberg Surveillance, The Acquirers Podcast and The Compound and Friends.

Mentions · 7d
4
Mentions · 30d
16
Mentions · 90d
32
Shows · 30d
12
Episodes · 30d
16
Vs prior week
+3
Discussion depth
Substantive discussion
As of 15 Oct 2026
Ask Zortix about NKE

Latest ideas · headlines, attributed

15 OCT4D AGOTHOUGHTFUL MONEY · JESSE FELDER
SHOWS SPLIT5 SHOWS · NOT ALL ON THE SAME SIDEOpen in Zortix →Thesis and listen link in the app
15 OCT4D AGOTHE JULIA LA ROCHE SHOW · LARRY MCDONALD
SHOWS SPLIT12 SHOWS · NOT ALL ON THE SAME SIDEOpen in Zortix →Thesis and listen link in the app
13 OCT6D AGOTHE COMPOUND AND FRIENDS
SHOWS SPLIT5 SHOWS · NOT ALL ON THE SAME SIDEOpen in Zortix →Thesis and listen link in the app

Discussed alongside NKE · 90 days

  1. LULUlululemon athletica inc.in 7 ideas
  2. ONONOn Holding AGin 4 ideas
  3. DPZDOMINOS PIZZA INCin 2 ideas
  4. AAPLApple Inc.in 1 idea
  5. ADS.DEAdidas AGin 1 idea
  6. AMZNAmazon.com Inc.in 1 idea
  7. ANFABERCROMBIE & FITCH CO /DE/in 1 idea
  8. AZOAUTOZONE INCin 1 idea

Definitions

Mention
One attributed idea naming this ticker, extracted from a podcast episode and dated by the episode’s air date. How we count →
Attributed idea
A specific argument a named speaker made on a named show, never an aggregate opinion, never Zortix’s view. What qualifies →
Discussion depth
How thoroughly an idea was argued on the episode, from a brief mention to a core thesis (a description of the conversation, not a rating of the stock). The bands →
Stance mix
Counts of attributed ideas by the side each argued on this name (bullish, balanced, or bearish as the speaker put it). A tally of the conversation’s sides, never a combined score, a rating, or Zortix’s view.
MENTIONS, DEPTH, STANCE MIX & COVERAGE REFLECT PODCAST DISCUSSION · NOT A RATING, FORECAST, OR RECOMMENDATION